Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ikonisys
Ikonisys Reports Positive Results from Clinical Study Designed to Evaluate the Efficacy of Circulating Tumor Cell Detection with Ikonisys' Automated Microscope
October 28th, 2008
Ikonisys, a leading provider of next-generation, cell-based diagnostic solutions, announced positive results from a clinical study conducted by a research group at the Weatherall Institute of Molecular Medicine at Oxford University, a laboratory supported by Cancer Research U.K. (CRUK), the country's leading cancer charity. The study validates the company's CellOptics(R) platform and proprietary digital microscope, the Ikoniscope(R), as a viable method for quickly and easily detecting and detailing circulating tumor cells (CTC) in the blood. The findings, published in the British Journal of Cancer (September 2008), represent a significant milestone for screening and disease monitoring for...
Source: Cancer Weekly (2008-10-28)
|
